Tareeva 100mg 30 tabs

Generic Name – Erlotinib

Drug Class: EGFR Inhibitors

Tarceva 100 mg (Erlotinib) is an oral targeted cancer medicine used to treat certain types of non-small cell lung cancer (NSCLC) with specific epidermal growth factor receptor (EGFR) mutations. It belongs to a class of medicines known as EGFR inhibitors, which block signals that encourage cancer cells to grow and multiply.

• Tarceva 100 mg is supplied in tablet form, with this pack containing 30 tablets.
• The dosage and treatment schedule depend on the cancer type, EGFR mutation status, the patient’s medical condition, and the prescribed treatment plan.
• Treatment must be supervised by an oncology specialist, with regular monitoring to assess treatment response and manage potential side effects.
• Erlotinib works by inhibiting the tyrosine kinase activity of the EGFR protein, which plays a role in cancer cell growth and survival.

By blocking these signals, Tarceva helps limit cancer cell proliferation and supports disease management as part of a specialist-directed treatment plan.

How Does Tarceva 100mg Tablet Work?

Tarceva 100mg (Erlotinib) is an oral targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC), depending on the cancer’s characteristics and treatment plan. It belongs to a class of medicines called epidermal growth factor receptor (EGFR) inhibitors, which work by blocking signals that encourage cancer cells to grow and multiply.

Erlotinib inhibits the activity of the EGFR protein, which plays an important role in cell growth and division. By blocking this signaling pathway, it can help slow cancer progression in patients whose tumors are suitable for this treatment.

• By inhibiting EGFR signaling, Tarceva can help restrict the growth and multiplication of certain cancer cells.
• Its effects may also involve healthy tissues, potentially causing side effects such as skin rash, diarrhea, loss of appetite and fatigue.
• Tarceva is classified as a targeted anticancer medicine known as an EGFR tyrosine kinase inhibitor.

Treatment suitability, dosage and duration depend on the cancer type, EGFR mutation status, previous treatments and the patient’s overall health.

Dosage of Tarceva 100 mg, 30 Tablets :

Tarceva 100 mg (erlotinib) is an oral targeted cancer medicine classified as an epidermal growth factor receptor (EGFR) inhibitor. It is used to treat certain types of non-small cell lung cancer, depending on the s EGFR mutation status and treatment indication of the tumor. It must be taken according to an oncologist’s prescription.

• Tarceva tablets are taken by mouth, generally once daily on an empty stomach, at least one hour before or two hours after food.
• The dosage depends on the cancer type, EGFR mutation status, treatment indication, overall health and response to therapy. The prescribed dose must be followed precisely.
• For certain indications, erlotinib is prescribed at a daily dose of 150 mg for non-small cell lung cancer or 100 mg for pancreatic cancer in combination with gemcitabine.

The appropriate dose depends on the approved treatment regimen. The oncologist may reduce or temporarily interrupt treatment depending on side effects, liver function, other medicines and the patient’s tolerance. Regular medical monitoring is essential during therapy.

Benefits of Using Tarceva 100 mg, 30 Tablets :

Tarceva 100 mg (erlotinib) is an oral targeted cancer medicine used to treat certain types of non-small cell lung cancer (NSCLC) with specific epidermal growth factor receptor (EGFR) mutations. It belongs to a class of medicines called EGFR tyrosine kinase inhibitors, which block signals that help cancer cells grow and multiply.

Erlotinib may be prescribed for eligible patients with locally advanced or metastatic NSCLC, depending on the tumor’s molecular characteristics and previous treatment. Its suitability depends on the confirmed EGFR mutation status, cancer stage, and the treating oncologist’s assessment.

Tarceva inhibits EGFR tyrosine kinase activity, helping interrupt signaling pathways that can promote the growth and division of susceptible cancer cells.

This medicine may be used as targeted treatment for eligible patients with advanced or metastatic NSCLC carrying specific activating EGFR mutations.

Erlotinib may help slow cancer progression in suitable patients, although treatment response varies according to tumor biology and individual circumstances.

Tarceva is available as an oral tablet, allowing treatment at home when prescribed, with appropriate medical supervision and follow-up.

Erlotinib is also used with gemcitabine to treat locally advanced, unresectable, or metastatic pancreatic cancer, according to the approved indication.

The prescribed dose and treatment schedule must be determined by the treating oncologist according to the cancer type, treatment indication, overall health, liver function, and response to therapy. Tarceva 100 mg should be taken exactly as directed. Regular monitoring is important to assess treatment response and manage adverse effects.

Side Effects of Tarceva 100mg – 30 Tablets :

Treatment with Tarceva 100mg (Erlotinib), an epidermal growth factor receptor (EGFR) inhibitor, may cause mild to serious side effects depending on individual health and treatment response. Commonly reported side effects include:

• Nausea, vomiting, and diarrhea
• Fatigue, weakness, and loss of appetite
• Acne-like skin rash and dry skin
• Abdominal pain and indigestion
• Mouth sores and eye irritation
• Cough and shortness of breath

Tarceva may increase the risk of infections, liver problems, and, rarely, serious lung inflammation or gastrointestinal perforation. Contact a healthcare professional promptly if you experience severe breathing difficulties, persistent diarrhea, significant abdominal pain, yellowing of the skin or eyes, or unusual bleeding.

Regular monitoring of liver function and other relevant health parameters is important during treatment. Take this medicine only under specialist supervision.

Conclusion :

Tarceva 100mg tablets (erlotinib) are a prescription targeted therapy classified as an epidermal growth factor receptor (EGFR) inhibitor, used to treat certain types of non-small cell lung cancer. Treatment suitability and dosage depend on the cancer type and individual patient factors.

Important Medical Warning :

Use any other product here strictly according to your doctor’s prescription. Follow your healthcare professional’s instructions regarding dosage, administration, and treatment duration. Do not self-medicate, change the dose, or discontinue treatment without consulting your doctor. This medication must be administered by qualified healthcare professionals.